- Esperion recently reported their Q1 earnings that revealed a big miss on EPS and revenue. Consequently, the share price got cut ~30% as Street analyst cut their targets.
- Despite having impressive clinical data, NEXLETOL and NEXLIZET have had a disappointing launch thus far. However, the company reported some encouraging commercial trends that could lead to future growth.
- The sell-off has forced me to change my plans for ESPR. I discuss how I intend to manage my ESPR position for the rest of 2021.
For further details see:
Esperion: A Change In Plans After A Disappointing Q1 Earnings